what is Melanotan II?
the evidence-based truth about the world's most popular unapproved tanning peptide
this is not a tanning guide
Melanotan II is an unapproved, non-selective melanocortin agonist developed at the University of Arizona in the early 1990s. it has never been approved by the FDA, EMA, TGA, or any other regulatory body for human use. despite widespread gray-market availability, no controlled clinical program has ever led to marketing authorization.
this course does not teach you how to use MT-II. it teaches you the receptor pharmacology, melanogenesis biology, chemistry, reported effects, safety signals, clinical evidence gaps, and legal reality so you can evaluate the science for yourself.
what this course covers
university of arizona origins
the molecule makes more sense when you start with the research program that produced it.
in the early 1990s, Victor Hruby and Mac Hadley at the University of Arizona synthesized Melanotan II as a shorter, more potent analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). the original research goal was developing a sunless tanning agent that could reduce UV exposure and skin cancer risk.
unlike its predecessor Melanotan I (afamelanotide), which is a linear 13-amino-acid peptide with selective MC1R binding, MT-II was designed as a cyclic heptapeptide with dramatically increased potency -- but at the cost of receptor selectivity. that tradeoff shaped everything that followed.
a non-selective melanocortin agonist
hitting four receptors at once is the central pharmacological fact about this molecule.
Melanotan II is a cyclic heptapeptide (seven amino acids) that binds with meaningful affinity to MC1R, MC3R, MC4R, and MC5R. this non-selective binding profile is what distinguishes it from afamelanotide (primarily MC1R) and bremelanotide/PT-141 (primarily MC4R, derived from MT-II research).
each receptor subtype mediates different physiological effects: MC1R drives pigmentation, MC3R is involved in energy homeostasis, MC4R modulates appetite and sexual function, and MC5R influences exocrine gland secretion. activating all four simultaneously creates a broad and unpredictable effect profile.
not approved anywhere
no regulatory body has authorized Melanotan II for any indication.
the FDA has issued warnings about Melanotan II products. the TGA (Australia) has explicitly warned consumers against its use. the EMA has never received a marketing authorization application. no country has approved MT-II for tanning, sexual dysfunction, appetite suppression, or any other indication.
products sold online as "MT-II" or "Melanotan 2" are unregulated research chemicals with no standardized manufacturing, purity testing, or dosing guidance. the gap between published receptor pharmacology and gray-market product quality is enormous.
the melanocortin family tree
understanding where MT-II sits relative to alpha-MSH, afamelanotide, and bremelanotide.
all melanocortin-based peptides trace back to alpha-MSH, a 13-amino-acid endogenous hormone. Melanotan I (afamelanotide) is a linear analogue with selective MC1R binding, approved as SCENESSE for erythropoietic protoporphyria. Melanotan II is a cyclic, shorter, non-selective analogue with broader receptor activity.
PT-141 (bremelanotide), approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, was directly derived from MT-II research. the key modification was selecting for MC4R activity while reducing the broader melanocortin agonism. PT-141 is the only FDA-approved drug to emerge from the MT-II lineage.
key terms
definitions for the technical words that show up across this course. tap to expand.
M
A
C
M
M
M
N
A
B
L
G
N
what you will learn
the rest of the course moves from receptor biology into chemistry, effects, safety, evidence, and regulatory reality.
Knowledge Check
confirm the origins, receptor profile, and regulatory fundamentals before moving deeper.
Practice
reinforce the distinctions that matter most for the rest of the course.